4G/5G Promoter PAI-1 Gene Polymorphism Is Associated with Plasmatic PAI-1 Activity in Italians: A Model of Gene-Environment Interaction

Summary

The PAI-1 gene promoter 4G/5G polymorphism was found to be associated with plasma PAI-1 activity in Northern and Central Europe populations, but no data are available on the association between this polymorphism and PAI-1 levels in Southern Europe countries (such as Italy) where the incidence of ischemic disorders is lower. This study shows that among populations with different incidence of atherothrombotic disorders the 4G/5G PAI-1 gene promoter polymorphism has the same importance in the regulation of plasma PAI-1 activity.

Moreover, we have analysed some gene-environmental interactions: the correlation between PAI-1 and cholesterol in non dyslipidemic subjects and the correlation between PAI-1 activity and tryglicerides in dyslipidemic subjects differed according to the 4G/5G genotype class. Thus, our findings suggest that, among subjects with or without metabolic disorders such as dyslipidemia, completely different gene-environment interactions may occur.

^* On leave of absence from the Institute of Cardiology, Catholic University, Rome, Italy.

• References

• 1 Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-63.
• 2 Hamsten A, de Faire U, Wldius G, Dahlen G, Szamosi A, Landou C, Blom-back M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9.
• 3 Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet 1994; 343: 940-3.
• 4 Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-41.
• 5 Cortellaro M, Cofrancesco E, Boschetti C. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients: a case-control study. Arterioscler Thromb 1993; 13: 1412-7.
• 6 Juhan-Vague I, Valadier J, Alessi MC, Allaud MF, Ansaldi J, Philip-Joet C, Halvoet P, Serradimigni A, Collen D. Deficient t-PA release and elevated PA inhibitor in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost 1987; 57: 67-72.
• 7 Dawson S, Hamsten A, Wiman B, Henney A, Humphries S. Genetic variation at the plasminogen activator inhibitor-1 (PAI-1) locus. Fibrinolysis 1990; 4 (Suppl. 02) 51-3.
• 8 Dawson S, Hamsten A, Wiman B, Henney A, Humphries S. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscl Thromb 1991; 11: 183-90.
• 9 Ginsburg D. Regulation of PAI-1 gene expression. Thromb Haemost 1991; 65: 740.
• 10 Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to inter-leukin-1 in HepG2 cells. J Biol Chem 1993; 268: 10739-45.
• 11 Eriksson P, Kallin B, van’t Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92: 1851-5.
• 12 Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, Humphries SE, Evans A, Luc G, Cambou JP, Arveiler D, Henney AM, Cambien F. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemost 1995; 74: 837-41.
• 13 WHO. MONICA Project: risk factors. Int J Epydemiology 1989; 18: 46-55.
• 14 Mansfield MW, Stickland MH, Grant PJ. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus. Thromb Haemost 1995; 74: 842-7.
• 15 Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries SE, Yudkin JS. Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes 1995; 44: 37-42.
• 16 Roncaglioni MC, Santoro L, D’Avanzo B, Negri E, Nobili A, Ledda A, Pietropaolo F, Franzosi MG, La Vecchia C, Feruglio GA, Maseri A. on behalf of GISSI-EFRIM Investigators. Role of family history in patients with myocardial infarction. An italian case-control study. Circulation 1992; 85: 2065-72.
• 17 Falk G, Svensson H, Almqvist A, Wiman B. Allele specific PCR for detection of a sequence polymorphism in the promoter region of the plasminogen activator inhibitor-1 (PAI-1) gene (abstract). Fibrinolysis. 1994 8 Suppl 1: 45.
• 18 Metodi statistici per la sperimentazione biologica. Camussi A, Moller F, Ottaviano E, Sari Gorla M. Zanichelli, Bologna, (Italy) 1989.
• 19 SAS Institute.. SAS/STAT Users Guide, Version 6. Cary, NC: SAS Institute Inc; 1989
• 20 Nicoloso G, Hauert J, Kruithof EKO, Van Melle G, Bachmann F. Fibrinolysis in normal subjects-comparison between plasminogen activator inhibitor and other components of the fibrinolytic system. Thromb Haemost 1988; 59: 299-303.
• 21 Alessi MC, Juhan-Vague I, Declerck PJ, Anfosso F, Gueunoun E, Collen D. Correlations between t-PA and PAI-1 antigen and activity and t-PA/PAI-1 complexes in plasma of control subjects and of patients with increased t-PA or PAI-1 levels. Thromb Res 1990; 60: 509-16.
• 22 Hamsten A, Eriksson P. Fibrinolysis and Atherosclerosis: an update. Fibrinolysis 1994; 8 (Suppl. 01) 253-62.
• 23 Juhan-Vague I, Thompson SG, Jespersen J. On behalf of the ECAT Angina Pectoris Study Group. Involvement of the hemostatic system in the insulin resistance syndrome. a study of 1500 patients with angina pectoris. Arterioscl Thromb 1993; 13: 1865-73.
• 24 Mussoni L, Mannucci L, Sirtori M, Camera M, Maderna P, Sironi L, Tremoli E. Hypertriglyceridemia and regulation of fibrinolytic activity. Arterioscl Thromb 1992; 12: 19-27.
• 25 Mehta J, Metha P, Lawson D, Saldeen T. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations. J Am Coll Cardiol 1987; 9: 263-8.
• 26 Zitoun D, Bara L, Basdevant A, Samama MM. Levels of factor VIIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dyslipidemias. Arterioscler Thromb Vasc Biol 1996; 1: 77-81.
• 27 Mykkanen L, Ronnemaa T, Marniemi J, Haffner SM, Bergman R, Laakso M. Insulin sensivity is not an independent determinant of plasma plasminogen activator inhibitor-1 activity. Arterioscl Thromb 1994; 14: 1264-71.